As Senior Vice President and Chief Financial Officer, Mr. Hess is responsible for overall financial management of the company, including financial reporting, financial planning and analysis and corporate and strategic development.
Prior to joining Genomind, Mr. Hess was the Chief Financial Officer and Executive Vice President of Keane. Keane is the largest provider of unclaimed property services in the United States and was sold in 2014. Prior to Keane, Mr. Hess was the Chief Financial Officer for Yaupon Therapeutics and Adolor Corporation which were development stage biotechnology companies each of which successfully launched an FDA approved drug. Mr. Hess also served as the Corporate Controller for Vicuron Pharmaceuticals which was sold to Pfizer in 2005. Prior to Vicuron, Mr. Hess served as a controller for several technology companies after working for KPMG for 10 years. He is a CPA and an adjunct professor at Penn State University and DeSales University. In addition, he is active in Life Sciences PA.
Mr. Hess received a BS in Accounting from Pennsylvania State University and an MBA from the University of Pittsburgh – Katz Graduate School of Business.